Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) Other
Conditions
Interventions
The intervention consists of three interlinked components:
Component 1: SMARTHealth Climate App (Digital Clinical Support for CVD and COPD)
This component centres on the use of the SMARTHealth Climat
Sponsors
National Institute for Health Research
Eligibility
Sex/Gender
All
Age
40 Years to 114 Years
Inclusion criteria
Inclusion criteria: Participants will be eligible for inclusion in the study if they meet any of the following criteria 1. High CVD risk: Adults aged =40 years who meet one or more of the following conditions: 1.1. A history of CVD confirmed by a physician 1.2. A 10-year estimated CVD risk of =10% and systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg 1.3. A 10-year estimated CVD risk of >20% 2. COPD: Adults aged =40 years with a diagnosis of COPD made by general practitioners at Puskesmas based on 2.1. Clinical anamnesis 2.2. Clinical examination findings 2.3. Spirometry assessment following national guidelines
Exclusion criteria
Exclusion criteria: 1. Individuals with severe physical or cognitive impairments that would prevent participation in screening, follow-up, or completion of study assessments 2. Pregnant women, due to differing cardiovascular and respiratory physiological parameters 3. Individuals currently enrolled in other clinical studies targeting cardiovascular or respiratory conditions 4. Those who decline or are unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CVD cohort: Mean systolic blood pressure measured using validated automated digital sphygmomanometers at baseline and after 1 year of intervention implementation COPD cohort: Health-related quality of life measured using WHOQOL-BREF at baseline and after 1 year of intervention implementation | — |
Secondary
| Measure | Time frame |
|---|---|
| CVD cohort: 1. Blood pressure control measured by the proportion of participants achieving guideline-recommended blood pressure control 2. Health-related quality of life measured using WHOQOL-BREF COPD cohort: 1. Incidence of acute exacerbation measured by the proportion of participants experiencing acute exacerbations during the study period using validated structured questionnaire and clinical records where available 2. Depressive symptoms measured using Center of Epidemiologic Studies Depression Scale, 10-item version (CES-D-10), at baseline and after 1 year Both cohorts: 1. Prescribed preventive medications and adherence measured by the proportion of participants who are both prescribed and adherent to guideline- recommended medications, assessed at baseline and after 1 year through prescription records and self-reported adherence questionnaires 2. Behavioural risk factors: 2.1. Tobacco use measured using a structured questionnaire adapted from WHO tobacco surveillance items (STEPS/GATS) 2.2. Physical activity measured using questionnaires adapted from WHO Global Physical Activity Questionnaire (GPAQ) and International Physical Activity Questionnaire (IPAQ) 2.3. Body mass index measured by calculating height (stadiometer) and weight (calibrated digital scale) using the formula kg/m² All secondary outcomes will be measured at baseline and after 1 year of intervention program implementation. | — |
Countries
Indonesia
Contacts
Public ContactSri;Asri Andarini;Maharani
;
Outcome results
None listed